Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.

Liver - 1 Aug 1999

Salmerón J, Ruiz-Extremera A, Torres C, Rodríguez-Ramos L, Lavín I, Quintero D, Palacios A

Abstract excerpt

BACKGROUND: More than 70% of patients with chronic hepatitis C are resistant to interferon therapy. Ribavirin, in association with interferon, has been demonstrated as effective, at a dose of 800-1200 mg/day, but the efficacy of a lower dose has not been established. METHODS: We assessed the effectiveness of the combination of 600 mg/day of ribavirin plus 3 MU of interferon over a period of 6 months, in a group...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Ribavirin

Source

Identifiers

PMID: 10459624
DOI: 10.1111/j.1478-3231.1999.tb00049.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.PMID 10459624Read ↗

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.Semantic proximity Read ↗

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Semantic proximity Read ↗

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.Semantic proximity Read ↗

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.Semantic proximity Read ↗

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.Semantic proximity Read ↗

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.Semantic proximity Read ↗

Pilot study of interferon gamma for chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.